STOCK TITAN

ProMIS Neurosciences: Great Point reports 6.77% stake

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Neutral)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
SCHEDULE 13G/A

Rhea-AI Filing Summary

ProMIS Neurosciences Inc. (PMN) is the issuer in a joint ownership report in which Great Point Partners, LLC, Dr. Jeffrey R. Jay, M.D., and Ms. Lillian Nordahl each report beneficial ownership of 650,731 common shares, or 6.77%, with shared voting and dispositive power. The percentage is based on 9,618,424 shares, including 8,967,693 shares outstanding reported as of August 13, 2026, and 650,731 shares issuable upon warrants.

The reported shares are underlying 18,691 Pre-Funded Warrants and 632,040 Warrants. Exercise is restricted if it would cause the holder, affiliates, and persons or entities in a group to beneficially own more than 9.99% immediately after exercise. Biomedical Value Fund, L.P. and Biomedical Offshore Value Fund, Ltd. are the record holders of warrants for 429,483 and 221,248 shares, respectively. Great Point is the funds’ investment manager; Dr. Jay is its Senior Managing Member and Ms. Nordahl its Managing Director. The reporting persons disclaim beneficial ownership except to the extent of their respective pecuniary interests.

Beneficially owned shares 650,731 shares Reported by each reporting person, with shared voting and dispositive power.
Reported ownership percentage 6.77% Based on 9,618,424 shares, including shares outstanding and shares issuable upon warrants.
Beneficial Ownership Cap 9.99% Warrant exercise is restricted if it would result in ownership above this level immediately after exercise.
Ownership calculation denominator 9,618,424 shares Includes 8,967,693 shares outstanding and 650,731 shares issuable upon warrants.
Shares underlying Pre-Funded Warrants 18,691 shares Part of the warrants held in aggregate by the reporting persons.
Shares underlying Warrants 632,040 shares Part of the warrants held in aggregate by the reporting persons.
BVF Warrant shares 429,483 shares Warrants held of record by Biomedical Value Fund, L.P.
BOVF Warrant shares 221,248 shares Warrants held of record by Biomedical Offshore Value Fund, Ltd.
Pre-Funded Warrants financial
"aggregate Pre-Funded Warrants to purchase 18,691 shares"
Pre-funded warrants are financial instruments that give investors the right to purchase a company's stock at a set price, but with most or all of the purchase price paid upfront. They function like a coupon or gift card for stock, allowing investors to buy shares later at a fixed price, which can be beneficial if they want to avoid future price increases. This makes them important for investors seeking flexibility and certainty in their investment plans.
Beneficial Ownership Cap financial
"the Beneficial Ownership Cap"
A beneficial ownership cap is a rule that limits how much of a company a single investor or related group can effectively control, even if legal ownership could be higher. Think of it as a speed limit for ownership that prevents any one party from accumulating a controlling stake; it matters to investors because it affects takeover risk, voting power, dilution, and potential returns by shaping who can influence corporate decisions.
Rule 13d-3 regulatory
"computed in accordance with Rule 13d-3"
Rule 13d-3 defines who is treated as the beneficial owner of a company’s shares for U.S. securities disclosure rules — essentially anyone who has the power to vote or direct how shares are voted, or the power to buy or sell them, even if they don’t hold the certificates. For investors this matters because crossing certain ownership thresholds triggers public filing and disclosure obligations and signals potential control or influence, much like having the keys to a car implies you can drive it even if it’s registered to someone else.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What percentage of PMN does Great Point Partners report beneficially owning?

Great Point Partners, LLC, Dr. Jeffrey R. Jay, M.D., and Ms. Lillian Nordahl each report beneficial ownership of 650,731 shares, or 6.77%, with shared voting and dispositive power.

How many PMN warrant shares are exercisable for BVF and BOVF under the ownership cap?

The statement identifies 429,483 shares (4.47%) underlying Biomedical Value Fund, L.P.’s warrants and 221,248 shares (2.30%) underlying Biomedical Offshore Value Fund, Ltd.’s warrants as exercisable under the cap.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google





74346M505

(CUSIP Number)
09/30/2026

(Date of Event Which Requires Filing of this Statement)


Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)




schemaVersion:


SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G



Great Point Partners, LLC
Signature:/s/ Dr. Jeffrey R. Jay, M.D
Name/Title:Dr. Jeffrey R. Jay, M.D - Senior Managing Member
Date:11/16/2026
Dr. Jeffrey R. Jay, M.D.
Signature:/s/ Dr. Jeffrey R. Jay, M.D
Name/Title:Dr. Jeffrey R. Jay, M.D
Date:11/16/2026
Ms. Lillian Nordahl
Signature:/s/ Ms. Lillian Nordahl
Name/Title:Ms. Lillian Nordahl
Date:11/16/2026
Exhibit Information

JOINT FILING STATEMENT PURSUANT TO RULE 13d-1(k) The undersigned hereby agree as follows: (i) Each of them is individually eligible to use the SCHEDULE 13G to which this Exhibit is attached, and such SCHEDULE 13G is filed on behalf of each of them; and (ii) Each of them is responsible for the timely filing of such SCHEDULE 13G and any amendments thereto, and for the completeness and accuracy of the information concerning such person contained therein; but none of them is responsible for the completeness or accuracy of the information concerning the other persons making the filing, unless such person knows or has reason to believe that such information is inaccurate. Dated: November 16, 2026 Great Point Partners, LLC By: /s/ Dr. Jeffrey R. Jay, M.D. Dr. Jeffrey R. Jay, M.D., as Senior Managing Member Dr. Jeffrey R. Jay, M.D. By: /s/ Dr. Jeffrey R. Jay, M.D. Dr. Jeffrey R. Jay, M.D. Ms. Lillian Nordahl By: /s/ Ms. Lillian Nordahl Ms. Lillian Nordahl

Keep reading